---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-25-000004"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:45:48.766966+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance

## Summary
- Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.
- Q4 2024 revenue at least $92M (+59% YoY, +20% sequential); exome/genome rev $75.8M (+93% YoY).
- Adjusted gross margin ≥64% FY (guidance ≥62%) and ≥68% in Q4 (up from 64% Q3).
- Q4 exome/genome volume 20,676 (+32% YoY, +7% seq); expects second consecutive adjusted net income quarter and first positive operating cash flow.
- Includes $6.8M discrete benefit from multi-year appeal recovery from a single payer.

## SEC filing metadata
- accession: 0001818331-25-000004
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000004/0001818331-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000004/wgs-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-25-000004
- JSON: https://secwatch.observer/filing/0001818331-25-000004.json
- Plain text: https://secwatch.observer/filing/0001818331-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.